TMEM230

TMEM230 is a transmembrane protein of secretory and recycling vesicles that functions in retromer-mediated cargo trafficking, Golgi-derived vesicle secretion, and autophagic cargo degradation. It localizes to synaptic vesicles in neurons and to early endosomes, where it is required for proper retromer localization and CI-M6PR trafficking via the small GTPase Rab8a, and its loss disrupts extracellular secretion of p62 and immature lysosomal hydrolases (PMID:28115417). Disease-linked TMEM230 mutations impair synaptic vesicle trafficking, increase alpha-synuclein levels, and cause neurodegeneration with disrupted retrograde axonal mitochondrial transport, while TMEM230 knockout rats lack neurodegeneration, indicating that Parkinson disease-associated variants act through a gain-of-toxic-function mechanism rather than haploinsufficiency (PMID:27270108, PMID:34002226, PMID:39106917).

1. 2016 High

   Establishing TMEM230 as a vesicular transmembrane protein: its localization to secretory/recycling and synaptic vesicles, and the demonstration that PD-linked mutants impair vesicle trafficking and elevate alpha-synuclein, placed TMEM230 squarely in the vesicular trafficking pathway relevant to Parkinson disease.

   Evidence Localization studies in primary neurons and HEK293 cells; live imaging of synaptic vesicle movement with overexpressed PD-linked mutants

   PMID:27270108

   Open questions at the time

   • Molecular mechanism by which TMEM230 regulates vesicle trafficking was unknown
   • Whether alpha-synuclein elevation is a direct or indirect consequence was not resolved
   • No in vivo loss-of-function model existed
2. 2017 High

   TMEM230 was placed mechanistically upstream of retromer-mediated cargo sorting and secretory autophagy: its knockdown disrupted retromer localization, CI-M6PR trafficking, and Golgi-derived secretion, all rescuable by Rab8a, and LRRK2 knockdown phenocopied these defects, linking TMEM230 to the LRRK2–Rab8a axis.

   Evidence siRNA knockdown of TMEM230 and LRRK2; immunofluorescence, cargo secretion assays, and Rab8a rescue experiments

   PMID:28115417

   Open questions at the time

   • Whether TMEM230 directly binds or activates Rab8a was not shown
   • Epistasis between TMEM230 and LRRK2 was inferred from parallel phenotypes in a single lab, not from double-knockdown experiments
   • Pathway convergence via Rab8a was challenged by later negative biochemical data
3. 2018 Medium

   The proposed direct functional link between TMEM230 and LRRK2/Rab GTPases was challenged: LRRK2 neither binds nor phosphorylates TMEM230, and TMEM230 overexpression does not alter levels of Rab8A or other Rab proteins, suggesting TMEM230's role in Rab8a-dependent trafficking is indirect.

   Evidence Co-immunoprecipitation, in vitro kinase assay, and western blotting after overexpression

   PMID:30460091

   Open questions at the time

   • Negative interaction results from overexpression systems do not exclude context-dependent or transient interactions
   • The mechanism by which TMEM230 loss leads to Rab8a-dependent phenotypes remained unresolved
   • Only steady-state Rab levels were measured, not activation or membrane recruitment
4. 2021 Medium

   TMEM230 perturbation was shown to impair retrograde axonal mitochondrial transport and cause neurodegeneration, with PD-linked mutants producing more severe effects than wild-type overexpression, indicating a toxic gain-of-function component.

   Evidence Overexpression and siRNA knockdown in SH-SY5Y cells and mouse primary hippocampal neurons; live imaging of axonal mitochondrial transport

   PMID:34002226

   Open questions at the time

   • How TMEM230 influences mitochondrial transport machinery is unknown
   • Both overexpression and knockdown cause similar phenotypes, complicating interpretation of mechanism
   • Single lab study; replication in independent models needed
5. 2024 Medium

   In vivo knockout resolved the loss-of-function versus gain-of-function debate: TMEM230 knockout rats showed no motor deficits, dopaminergic neuron loss, or vesicular trafficking alterations, establishing that PD-associated mutations act through a gain-of-toxic-function mechanism.

   Evidence CRISPR-Cas9 knockout rat model; behavioral testing, immunohistochemistry, western blotting for autophagy/Rab/vesicular markers

   PMID:39106917

   Open questions at the time

   • A knock-in model of PD-associated mutations is needed to confirm gain-of-function toxicity in vivo
   • Possible compensatory mechanisms in the knockout rat were not investigated
   • Single study; no conditional or neuron-specific knockout was performed
6. 2025 Medium

   TMEM230 was identified as a physical subunit of ATP8/ATP11 lipid flippase complexes on early endosomes, providing a molecular basis for its endosomal function.

   Evidence Cross-linking mass spectrometry of purified human endosomes, native gel MS, AlphaFold structural prediction, validation in induced neurons (preprint)

   PMID:bio_10.1101_2025.02.07.636106

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Functional consequence of TMEM230 loss on flippase activity has not been measured
   • Whether lipid flippase association explains TMEM230's role in retromer trafficking and disease is untested

• The direct molecular mechanism by which TMEM230 regulates vesicle trafficking — whether through lipid flippase function, Rab8a modulation, or another route — and how PD-linked mutations gain toxic function remain open questions.
• No reconstituted biochemical activity for TMEM230 has been demonstrated
• Structural basis of PD-linked mutant toxicity is unknown
• Relationship between flippase complex membership and retromer/secretory autophagy phenotypes is untested